ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025
Quality of life in very long-term (including > 20 years' follow-up) early-stage breast cancer survivors from Spain.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The EORTC updated breast cancer quality of life questionnaire EORTC QLQ-BR42: A psychometric study with Spanish patients.BMC cancer · 2026Article
- The Experience of Spanish Cancer Patients and Professionals With Quality of Life Assessment in Clinical Practice.Journal of patient experience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveTo study the quality of life of Spanish very long-term early-stage breast cancer survivors, differences between groups based on follow-up duration and global QOL determinants.
methodsParticipating in this cross-sectional study were 211 stage I-IIIA-C breast cancer patients from a single centre subjected to breast surgery ≥ 10 years earlier. Patients completed EORTC QLQ-C30 and QLQ-BR45. Patients ≥ 65 years also completed QLQ-ELD14. Comparisons were studied between groups based on the age at assessment (< 70, 71-75 and ≥ 76 years) and years since the beginning of treatment (≤ 15, 16-20 and > 20 years) (both via the Kruskal-Wallis test and the latter adjusted by age). Demographic, clinical and QOL determinants of QLQ-C30 global QOL scale were also studied (linear regression models).
resultsWhole sample QOL scores were high (> 80/100 points) in most areas. Moderate limitations (> 30 points) occurred in QLQ-BR42 in sexual functioning and enjoyment and skeletal symptoms, and in QLQ-ELD14 in worries about others, maintaining purpose and joint stiffness. The ≥ 76 group showed the lowest functioning (physical, sexual, mobility, maintaining purpose), breast satisfaction and family support, and highest fatigue and joint stiffness of the three groups. The > 20 years since beginning of treatment group showed the highest functioning (physical, mobility, and maintaining purpose) and lowest fatigue and joint stiffness. Combining physical functioning, mobility, sleep disturbance, and systemic side effects, R
conclusionsQuality of life in very long-term early-stage breast cancer patients was high in the whole sample and follow-up groups, indicating patients adapted well to their situation. Results are highly relevant due to the sample's high mean age.
Indexed as
Identifiers
40506595What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.